| pubmed-article:17168428 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0032854 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C1561558 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:17168428 | lifeskim:mentions | umls-concept:C0348080 | lld:lifeskim |
| pubmed-article:17168428 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17168428 | pubmed:dateCreated | 2006-12-15 | lld:pubmed |
| pubmed-article:17168428 | pubmed:abstractText | Irinotecan (CPT-11) has been tested as a single agent in several studies, and response rates of 18-23% have been reported in first-line gastric cancer therapy. In the present study we report the safety and efficacy results combining CPT-11 with 5-fluorouracil (5-FU) and folinic acid (FA). | lld:pubmed |
| pubmed-article:17168428 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17168428 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17168428 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17168428 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17168428 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17168428 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17168428 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17168428 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17168428 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17168428 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17168428 | pubmed:issn | 0300-8916 | lld:pubmed |
| pubmed-article:17168428 | pubmed:author | pubmed-author:BajettaEmilio... | lld:pubmed |
| pubmed-article:17168428 | pubmed:author | pubmed-author:BuzzoniRobert... | lld:pubmed |
| pubmed-article:17168428 | pubmed:author | pubmed-author:BerettaElenaE | lld:pubmed |
| pubmed-article:17168428 | pubmed:author | pubmed-author:MarianiLuigiL | lld:pubmed |
| pubmed-article:17168428 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:17168428 | pubmed:author | pubmed-author:FerrarioErmin... | lld:pubmed |
| pubmed-article:17168428 | pubmed:author | pubmed-author:GevorgyanArpi... | lld:pubmed |
| pubmed-article:17168428 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17168428 | pubmed:volume | 92 | lld:pubmed |
| pubmed-article:17168428 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17168428 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17168428 | pubmed:pagination | 379-83 | lld:pubmed |
| pubmed-article:17168428 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:meshHeading | pubmed-meshheading:17168428... | lld:pubmed |
| pubmed-article:17168428 | pubmed:articleTitle | Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. | lld:pubmed |
| pubmed-article:17168428 | pubmed:affiliation | Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. | lld:pubmed |
| pubmed-article:17168428 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17168428 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17168428 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17168428 | lld:pubmed |
